CSCC: Translating Cemiplimab Data Into PracticeApril 19th 2023
Following their review of recent clinical data, expert panelists consider how neoadjuvant cemiplimab will fit into the real-world treatment paradigm of resectable CSCC, including the possibility of delaying or avoiding surgery in patients who have an adequate response to cemiplimab.
Neoadjuvant IO Therapy Trials in Resectable CSCC and Cemiplimab Data UpdatesApril 12th 2023
A brief overview of clinical trials evaluating the potential use of neoadjuvant immune checkpoint inhibitors—pembrolizumab, atezolizumab, and cemiplimab—in CSCC, followed by a focused discussion of recent cemiplimab trial data.
Lessons Learned in Other Cancers and Suggested Endpoints in Future TrialsApril 12th 2023
Key opinion leaders take time to review how immune checkpoint inhibitors have transformed outcomes in rectal cancer and non-cutaneous squamous cell cancers and consider how to better structure clinical trial endpoints in CSCC.